Atp 38 contains Levocarnitine. Atp 38 uses:
The supplemental Atp 38 use is widely established in the management of cardiac ischemia and peripheral arterial disease. It is generally indicated for cardio protection. It lowers triglyceride levels and increases levels of HDL cholesterol. It is used with benefits in those with primary and secondary carnitine deficiency syndromes. There is also evidence of its use in liver, kidney and immune disorders or in diabetes and Alzheimer's disease. There is little evidence that supplemental Atp 38 boosts energy, increases athletic performance or inhibits obesity. The indications of Atp 38 may be summarized as follows:
|Brand Name:||Atp 38|
|Therapeutic Class:||Drugs for muscular energy metabolism|
|Last Updated:||2020-11-22 18:15:00|
Atp 38 contains Levocarnitine 500.0 Mg. Atp 38 doses
Monitoring should include periodic blood chemistries, vital signs, plasma carnitine concentrations and overall clinical condition.Syrup-
Generally Atp 38 is well tolerated. However, few side effects including transient nausea and vomiting, abdominal cramps, and diarrhoea may occur
Atp 38 is a naturally occurring substance required in mammalian energy metabolism. It has been shown to facilitate long-chain fatty acid entry into cellular mitochondria, thereby delivering substrate for oxidation and subsequent energy production in the form of Adenosine Tri phosphate or ATP. Fatty acids are utilized as an energy substrate in all tissues except the brain. In skeletal and cardiac muscle, fatty acids are the main substrate for energy production.
The safety and efficacy of oral Atp 38 has not been evaluated in patients with renal insufficiency. Chronic administration of high doses of oral Atp 38 in patients with severely compromised renal function or in ESRD patients on dialysis may result in accumulation of the potentially toxic metabolites, trimethylamine (TMA) and trimethylamine-N-oxide (TMAO), since these metabolites are normally excreted in the urine
Reports of INR increase with the use of warfarin have been observed. It is recommended that INR levels be monitored in patients on warfarin therapy after the initiation of treatment with levocarnitine or after dose adjustments.
Atp 38 is categorized by the USFDA as Pregnancy Category B. There are no adequate and well-controlled studies in pregnant women. Supplemental Atp 38 should be used by pregnant women only if clearly indicated and only under medical supervision. It is not known whether Atp 38 is excreted in human milk. Supplemental Atp 38 is not advised for nursing mothers. Those with seizure disorders should only use Atp 38 under medical advisement and supervision.
There is no known disease or syndrome in which Atp 38 administration is contraindicated. It is contraindicated in patients with hypersensitivity to any of its components.
There have been no reports of toxicity from levocarnitine overdosage. Atp 38 is easily removed from plasma by dialysis. The intravenous LD50 of levocarnitine in rats is 5.4 g/kg and the oral LD50 of levocarnitine in mice is 19.2 g/kg. Large doses of levocarnitine may cause diarrhea.
Tablet: Store in a cool & dry place, protected from light & moisture.
Solution: Store in a cool & dry place, protected from light.
Atp 38 Tablet price in India 225.25